Figure 1 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control

Carboplatin AT significantly extends survival in tumor-bearing mice. A, Schematic showing derivation of the resistant cell panel. B, Mice were injected subcutaneously in both flanks with 100% OVCAR4 cells (sensitive; green, top row), 80:20 OVCAR4:Ov4Carbo‐Luc cells (blue, middle row), or 100% Ov4Carbo‐Luc cells (resistant; red, bottom row). The same color shade is used for the target and nontarget tumors in the same mouse. Mice were randomized to receive vehicle (i.p. every 4 days x3; left column; n = 2 mice per ratio), ST (60 mg/kg carboplatin i.p. every 4 days x3; middle column; n = 2 mice per ratio), or AT as per table (right column; n = 3–5 mice per ratio). Gray bars, duration of vehicle and ST; dotted line, initiation of AT at time 0. Each line indicates one tumor; X indicates mouse culled. C, Kaplan–Meier survival curve for experiment in B, measured from the time of subcutaneous tumor cell injection. Green, 100% OVCAR4; blue, 80:20 OVCAR4:Ov4Carbo‐RFP; red, 100% Ov4Carbo‐Luc cells. Dashed lines, ST; solid lines, AT. P, significance for the comparisons indicated as assessed by the log-rank test Mantel–Cox.